Ikonisys to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

Ikonisys, a leading provider of non-invasive, cell-based diagnostic solutions, announced today that Paul White, Ikonisys president, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference on Monday, May 19 at 4:35 p.m. During the presentation, Mr. White will showcase the research and advancements the company has pioneered in the growing field of non-invasive, rare-cell diagnostics.

Predicted to be a $35 billion industry by 2015, according to market research firm Research and Markets, the molecular diagnostics market is poised to lead laboratory innovations that will change the way certain diseases are detected and diagnosed — ultimately leading to better patient wellness. Ikonisys is uniquely positioned to lead the innovation cycle, enabling for the first time early, accurate and non-invasive detection of various cancers, including cervical, bladder, breast and prostate; and genetic disorders, such as Down syndrome.

Through the Ikoniscope(R), Ikonisys’ high-throughput, automated, digital microscope, and its comprehensive CellOptics(R) platform, Ikonisys is providing “one-in-a-million” cell detection — literally identifying the one cell out of a million that matters. This type of rare-cell detection gives doctors and patients early access to critical information — an important factor in making well-informed decisions about healthcare and disease treatment.

Leveraging the company’s unique digital-microscopy platform, Ikonisys has developed several safe, non-invasive and accurate rare-cell based tests that aim to improve and, ultimately, replace several of today’s invasive and frequently inaccurate tests. Current tests in development include:

— oncoFISH cervical — Prognostic test that works in conjunction with traditional screening methods such as the Pap and HPV test to determine progression to malignancy.

— oncoFISH prostate — Screening test that works in conjunction with prostate specific antigens (PSAs) as a filter for first time evaluation of PSA. This test also determines the efficacy of treatment and drug sensitivity.

— fastFISH fetal – Screening test that detects the presence of chromosomal abnormality trisomy 21 in the first trimester of pregnancy.

Ikonisys’ innovative tests are supported by its CellOptics platform, a unique integration of intelligent imaging, microscopy, biology and informatics. CellOptics provides the tools and protocols necessary for seamless, highly-integrated procedures for automated and unattended cell based diagnostics, presenting labs, physicians and technologists with a new approach for cell analysis, a process that has traditionally required long training, tedious work and risk of human error.

For more information on Ikonisys, visit www.ikonisys.com.

About Ikonisys

Ikonisys is changing the practice of diagnostic medicine through its unique CellOptics’ platform. Through an innovative combination of intelligent imaging, microscopy, biology and informatics, Ikonisys enables physicians and researchers to deliver accurate, fast and personalized results for early cancer diagnosis, genetic disorder screening and fertility testing.

Ikonisys’ solutions enable its customers to launch novel, new tests designed to achieve rare cell detection. Ikonisys offers both large and regional reference labs, hospitals, research institutions and practice groups the ability to expand test volume capacity during an industry-wide shortage of trained technical personnel.

In 2006, Ikonisys obtained FDA clearance for fastFISH(R) amnio, an imaging application for the Ikoniscope(R) that provides automated identification of numerical aberrations of chromosomes associated with common birth defects. Additionally, in early 2007, the company received FDA clearance for oncoFISH bladder, an Ikoniscope application that helps in the initial diagnosis of bladder cancer.